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Yuanhu  Zhitong  prescription  (YZP)  is well  known  for  its  analgesic  effect.  However,  its  multiple  bioactive
components  in  vivo  remain  unclear.  In  this  paper,  a rapid  resolution  liquid  chromatography/quadrupole
time-of-ﬂight  (RRLC-ESI-Q/TOF)  was  employed  to  identify  the bioactive  components  and partial  metabo-
lites after  oral  administration  of YZP  extracts.  Meanwhile,  a  RRLC-ESI-Q/TOF  method  was established  and
validated for  the simultaneous  quantiﬁcation  of  protopine,  -allocryptopine,  tetrahydropalmatine,  cory-RLC-ESI-Q-TOF-MS
uanhu Zhitong prescription
erebrospinal ﬂuid
harmacokinetic study
daline,  tetrahyberberine  and  byakangelicin  in rat plasma  and  applied  for their pharmacokinetic  research.
The  results  showed  that  twenty-one  bioactive  components  of YZP  were  absorbed  into  the  blood  circula-
tion  and seventeen  components  were  detected  in  cerebrospinal  ﬂuid (CSF).  Moreover,  the  kinetic  proﬁles
of  six  analytes  were  obtained  and  the  results  suggested  that the  six  analytes  peaked  between  3.5 and
5.0  h and  Cmax ranged  from  214.6  to 858.3.  The  works  could  provide  key  information  for identiﬁcation  of
bioactive  constituents  and  understanding  the  metabolism  as  well  as pharmacological  actions  for  YZP.
 201©
. Introduction
Traditional Chinese medicine (TCM) has been used in China
or thousands of years and has played an indispensable role in
revention and treatment of diseases, especially for complicated
nd chronic conditions [1,2]. The herbs used in TCM are usually
 complex prescription containing hundreds or even thousands of
hemically distinct components in each ingredient, which become huge challenge to determine which one is responsible for a cer-
ain therapeutic effect [3]. Most of TCM formulations are taken
rally, and some constituents persist at detectable levels, along
∗ Corresponding authors. Tel.: +86 10 84035184; fax: +86 10 64013996.
E-mail addresses: hongjun0420@vip.sina.com, hyxu627@sohu.com (H. Yang),
uangluqi@263.net (L. Huang).
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with their metabolites, after digestion and absorption. Therefore,
it is necessary to trace the constituents of TCM formulation in vivo
and evaluate their pharmacokinetic proﬁles which can gain more
in-depth insights into the active components and the therapeutic
mechanisms for TCM formulation, especially for the drugs work-
ing in the brain system [4]. Recently, a RRLC-ESI-Q/TOF method has
been reported to boast a higher sensitivity than other methods for
identifying known and unknown compounds in complex matrices
[5,6]. Thus, it could be a valuable analytical technique for iden-
tifying active constituents and evaluating their pharmacokinetic
properties of TCM herbs in vivo.
Yuanhu Zhitong prescription (YZP) consists of Radix Angelicae
dahuricae and Rhizoma corydalis (processed with vinegar) and is
widely used for the treatment of gastralgia, costalgia, headache,
and dysmenorrhea caused by qi stagnancy and blood stasis, as
recorded in the Chinese Pharmacopoeia [7]. Previous studies indi-
Open access under CC BY-NC-ND license.cated that YZP exhibited therapeutic effects through a wide variety
of actions, including anti-nociceptive [8], anti-inﬂammatory [9],
anxiolytic [10], spasmolysis [11], and vasorelaxation [12]. Fur-
thermore, Radix Angelica dahuricae extracts produced synergistic
icense.
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ctions on the analgesic effect of Rhizoma corydalis alkaloid by
ncreasing plasma concentrations of dl-tetrahydropalmatine [13].
lkaloids in Rhizoma corydalis and coumarins in Radix Angelicae
ahuricae, had been identiﬁed as the active components; moreover,
lkaloids, such as dl-tetrahydropalmatine, protopine and berber-
ne, and coumarins, such as imperatorin and isoimperatorin, had
een studied to determine their pharmacological effects [14–18].
ecently, we had developed a system to detect 17 constituents of
ZP tablet using a RRLC technique coupled with a triple quadrupole
ass spectrometry (RRLC-QQQ) [19].
With the recent advances in new mass analyzers, hyphenated
echnologies and data acquisition software, the qualitative and
uantitative analysis of bioactive compounds in TCM herb in vivo
re more easy to carry out. In addition, this could be applied to
harmacokinetic study of YZP based on quantitative analysis that
ould identify potentially effective constituents in this herbal for-
ula. These studies might play a very signiﬁcant role in certain
herapeutic effects and warrant further study.
. Experiments
.1. Chemicals and materials
HPLC-grade acetonitrile, formic acid, and methanol were
btained from Merck (Darmstadt, Germany). Water was  puriﬁed
y a Milli-Q system (Millipore, Billerica, MA,  USA). The stan-
ards of imperatorin, isoimperatorin, psoralen, protopine, and
l-tetrahydropalmatine were purchased from the National Insti-
ute for the Control of Pharmaceutical and Biological Products
Beijing, China). Byakangelicin, byakangelicol, and coptisine were
cquired from Chengdu Herbpurify Co. (Chengdu, China). Xantho-
oxin, oxypeucedanin, and tetrahydroberberine were purchased
rom Shanghai Winherb Co. (Shanghai, China). Bergapten was
btained from Shanghai Baiyi Biotech (Shanghai, China). Coryda-
ine was purchased from Sigma–Aldrich Co. (St. Louis, MO,  USA).
-Allocryptopine was supplied by Shenzhen Meihe Biotech (Shen-
hen, China). The purities of all standards were no less than 98%
nd suitable for RRLC-ESI-Q-TOF analysis.
Angelica dahurica (Fisch. ex Hoffm.) Benth. et Hook. f. and Cory-
alis yanhusuo W.  T. Wang were obtained from the Anguo Medicinal
aterial Market (Hebei, China) in February 2011, and the drugs
ere identiﬁed by Pharmacist Xirong He (research assistant at the
hina Academy of Chinese Medical Sciences). Voucher specimens
ere deposited in the Institute of Chinese Materia Medica (China
cademy of Chinese Medical Sciences).
.2. Instrument and RRLC-ESI-Q/TOF conditions
Chromatographic experiments were performed on an Agilent
200 Rapid Resolution Liquid Chromatography System (Agilent
rop., Santa Clara, CA, USA) equipped with a quaternary pump, an
nline vacuum degasser, an autosampler and an automatic ther-
ostatic column oven. The separation was carried out on Poroshell
B C18 column (3.0 mm × 150 mm,  2.7 m,  Agilent) at 35 ◦C with
 ﬂow rate of 0.4 mL/min and injection volume was 5 L. Mobile
hase was a mixture of 0.1% formic acid–water (A) and acetoni-
rile (B). The gradient program of mobile phase was  carried out
s follows: 0–10 min, 20–30% B; 10–25 min, 30–60% B; 25–35 min,
0–100% B; 35–40 min, 100% B.
MS detection was conducted on an Agilent 6520 quadrupole
ime-of-ﬂight mass spectrometer equipped with an electrospray
onization source (ESI). Ionization was performed in the positive
lectrospray mode. On the basis of the best response for most
ompounds, the ﬁnal parameters were as follows: fragmentor
150 V), Vcap (3500 V), nebulizer (30 psi), drying gas (N2, 10 L/min,gr. B 935 (2013) 1– 9
350 ◦C). The TOF-MS was calibrated daily, according to the manu-
facturer’s recommendations. The testing mass range was  set from
m/z 50 to 1000 with a scanning rate of 2 s−1. Reference masses at
m/z 121.05087 (purine, 1.125 × 10−6 mol/L, Agilent Corp.) and m/z
922.00980 (hexakis (1H, 1H, 3H-tetraﬂuoropropoxy)-phosphazine,
5 × 10−6 mol/L, Agilent Corp.) were continually introduced, along
with the LC stream for accurate mass calibration. The collision
energy for each compound varied according to this formula:
[5 × (mass/100)] + 5. For example, the collision energy for an ion
with nominal m/z of 300 would be 20 V.
2.3. Preparation of YZP extract and the solutions for analysis
in vitro
The procedures of YZP extract preparation were as follows:
Herbs were ground into powders, respectively. Based on the opti-
mum extraction conditions in the previous research [12], a total
of 400 g of Corydalis yanhusuo and 200 g of Radix Angelica dahuricae
were macerated with 2.4 L of 70% ethanol for 2 h, and then extracted
twice under thermal reﬂux for 2 h. The extracts were ﬁltrated out
by running through absorbent cotton inserted in a funnel. The two
extracts were combined and evaporated to less than 200 mL in a
rotary evaporator R-210 (Buchi Ltd., Labortechnik AG, Switzerland)
at 50 ◦C under reduced pressure. Subsequently, the concentrated
extracts were freeze-dried using a freeze dryer (TF-FD-1; Tianfeng
Instrument Co., Shanghai, China) at −30 ◦C, and then pressed into
powder with a 60-mesh sieve.
2.4. Preparation of standards, calibration standard and quality
control (QC) samples
Standard stock solutions for 15 components (protopine,
-allocryptopine, dl-tetrahydropalmatine, coptisine, berberine,
tetrahydroberberine, corydaline, bergapten, byakangelicin, xan-
thotoxin, oxypeucedanin, byakangelicol, imperatorin, psoralen,
and isoimperatorin) were prepared respectively by weighing the
required amounts into volumetric ﬂasks and dissolving in 75%
methanol.
Calibration curve stock solutions of six analytes including
protopine, -allocryptopine, dl-tetrahydropalmatine, tetrahyber-
berine, corydaline and byakangelicin were prepared in 75%
methanol at 1 mg/mL. Prior to use, all stock solutions were diluted
with 75% methanol to obtain the combined working solution with
the concentration of 10 g/mL for the six analytes. The combined
solution was further diluted with methanol in formation of the fol-
lowing standard solutions, with the concentration of 50, 100, 250,
500, 1000, 2000 and 5000 ng/mL respectively for ﬁve standards
including protopine, -allocryptopine, dl-tetrahydropalmatine,
tetrahyberberine, corydaline and 15, 30, 75, 150, 300, 600 and
1500 ng/mL for byakangelicin. All the mixed standard solutions
were stored at 4 ◦C.
100 L combined working solution was evaporated to dry-
ness at 37 ◦C under the stream of nitrogen, to which 200 L
blank rat plasma were spiked sequentially, and were vigorously
vortex mixed for 30 s. For method validation, QC samples were
prepared independently according to the same sample preparing
protocol, with a spiked concentration of 250 ng/mL for protopine,
-allocryptopine, dl-tetrahydropalmatine, tetrahyberberine, cory-
daline and 75 ng/mL for byakangelicin.
2.5. Preparation of plasma and CSF samplesThe rat plasma samples were prepared by liquid–liquid extrac-
tion with ethyl acetate. A 200 L aliquot of ethyl acetate was added
to a clean tube containing 100 L of plasma sample, thoroughly
mixed by vortex for 3 min, then centrifuged at 2000 × g for 15 min
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t 4 ◦C. The supernatant was transferred to a clean Eppendorf tube.
his procedure was repeated twice, after which the supernatant
as evaporated to dryness at 37 ◦C under a stream of nitrogen. The
esidue was dissolved in 100 L of 75% methanol. Subsequently,
he tubes were vigorously vortex-mixed for 2 min, and the super-
atant collected by centrifugation at 12,000 × g for 15 min  was
irectly injected into the RRLC-ESI-Q/TOF system for further anal-
sis. Preparation of the CSF samples was the same as that of blood
amples.
.6. Method validation
Calibration curves were established ﬁrst by spiking blank
amples with appropriate amounts of six standards including pro-
opine, -allocryptopine, tetrahydropalmatine, tetrahyberberine,
orydaline and byakangelicin using six different concentrations
escribed above for plasma samples; then calibration curves were
onstructed by plotting the peak area versus the spiked concen-
rations of least square linear regression analysis with a weighting
actor of 1/x2. Deviations of these back-calculated concentrations
rom calibration standard samples were set within ±15% of nomi-
al concentrations (±20% for the lower limit of quantitation). The
oncentrations of QC samples and test samples were calculated
rom the linear regression equation of the peak area ratio against
oncentrations.
Accuracy and intra/inter-day precision were evaluated by
ssessing three batches on separate days, each containing ﬁve
eplicates of QC samples. Concentrations were calculated with cal-
bration curves obtained daily. Relative standard deviation (RSD)
elected for intra/inter-day precision assessment should not exceed
5%.
The lower limit of quantitation (LLOQ) of the assay was  assessed
s the lowest concentration of the calibration curve that can be
uantitatively determined with acceptable precision less than 20%
nd accuracy within ±20%. The LLOQ was established based on six
eplicates on three consecutive days.
The matrix effect (ME) was expressed as the ion suppres-
ion/enhancement on the ionization of analyte. The matrix effect
f the analytes was investigated by comparing the corresponding
eak areas of the post-extraction spiked samples from six different
ots of blank plasma to those of the QC working solutions recon-
tituted in mobile phase. Experiments were performed using QC
amples in six replicates. The extraction recoveries were calculated
y comparing the peak areas of blank plasma samples spiked with
he analytes pre-extraction with those of the post-extraction spiked
amples at the same concentrations. Experiments were performed
sing QC samples in six replicates.
The stability in rat plasma was investigated by comparing the
easured concentrations of QC samples in six replicates with the
piked concentrations under the following two storage conditions:
1) short-term temperature stability at room temperature for 6 h;
2) post-preparative stability at 10 ◦C for 24 h. The analytes was
onsidered stable when the percent deviation was within ± 15%.
.7. Pharmacokinetic study
Male Sprague-Dawley rats (230 ± 20 g) were obtained from the
xperimental Animal Center of Peking University Health Science
enter (Beijing, China). Animals were housed in a breeding room
ith temperature of 24 ± 2 ◦C, humidity of 60 ± 5%, and 12/12 h
ark-light cycle. Tap water and food were supplied ad libitum, but
nimals were fasted (with free access to water) for 12 h prior to
he experiments. The animal welfare and experimental procedures
ere in compliance with the Guide for the Care and Use of Labo-
atory Animals (National Research Council of the USA, 1996) and
elated ethical regulations of China Academy of Chinese Medicalgr. B 935 (2013) 1– 9 3
Sciences. The protocols were approved by the Animal Ethics Com-
mittee of Laboratory Animals of the Institute of Laboratory Animal
Resources of Beijing (Beijing, China).
Rats were orally administered YZP extract at a dose of
2.35 g/kg (equivalent to crude drug 24 g/kg) that the adminis-
tration doses of six individual compounds including protopine,
-allocryptopine, tetrahydropalmatine, corydaline, tetrahyber-
berine and byakangelicin were 4.54, 5.82, 6.98, 14.05, 2.66
and 1.78 mg/kg, respectively. At the same time, three standard
compounds at a dose of 1.0 mg/kg including protopine, tetrahy-
dropalmatine and corydaline, individually. At 0.25, 0.5, 1, 2, 3, 4, 6, 8
and 12 h after YZP administration, blood samples from the common
carotid artery were collected in polythene tubes with anticoagu-
lant heparin sodium (100 unit/mL). Then, the blood samples were
centrifuged (TGL-16G; Shanghai Precision Instruments Co., Ltd.,
Shanghai, China) at 2000 × g for 15 min  at 4 ◦C. The supernatants
were stored at −20 ◦C. CSF samples were collected from cerebellum
medulla oblongata cistern via percutaneous puncture at 1 h post-
YZP administration. Major pharmacokinetic parameters, including
Cmax, Tmax and AUC0–t, were calculated by the Drug and Statistics
(DAS) 3.0 software (edited by Chinese Mathematical Pharmacology
Society).
3. Results and discussion
3.1. Optimization of RRLC-ESI-Q/TOF condition
To obtain reliable chromatographic results and appropriate
ionization, four mobile phase systems of acetonitrile–water,
methanol–water, acetonitrile-acid aqueous solution and
methanol-acid aqueous solution were tested and compared.
The results suggested that acetonitrile-acid aqueous solution was
superior to the others. Meanwhile, formic acid was  added into
the mobile phase to improve the peak shape and restrain the
peak tailing, as well as increase ion response for alkaloids and
coumarins. This ﬁnding was conﬁrmed by the optimal solvent
systems consisting of a mixture of 0.1% formic acid–water (A)
and acetonitrile (B). The absorbed constituents of YZP belonged
to different chemical families and displayed distinct polarities in
complex biological matrix; thus, gradient elution was employed
to obtain effective separation, guarantee high ionization, and
minimize ion suppression. For the ESI-Q/TOF conditions, ESI was
determined in both negative and positive ion modes, and the
results indicated that the conditions were obtained from the ESI
positive ionization mode which could achieve a higher response
and provide more information for all compounds than the ESI
negative mode in MS  spectra.
3.2. Optimization of sample preparation
Various methods of sample preparation were tested to select
an efﬁcient extraction method for obtaining superior recovery of
target compounds and reducing matrix effects from plasma sam-
ples. The methods included protein precipitation with acetonitrile
or methanol and liquid–liquid extraction. Direct protein precip-
itation with acetonitrile or methanol could only measure a few
constituents possibly because of poor recovery and strong ion sup-
pression. Finally, liquid–liquid extraction was adopted because this
technique could increase the signal intensity. Different solvent
including ethyl acetate, chloroform and diethyl ether were investi-
gated and ethyl acetate was  selected as extraction solvent due to its
high extraction efﬁciency and the low interference, which was in
accord with the previous report [20]. Subsequently, different vol-
umes (100, 200 and 300 L) of the solvent and extraction times (1,
2 and 3) were investigated, respectively. The results suggested that
4 Y. Tao et al. / J. Chromatogr. B 935 (2013) 1– 9
Fig. 1. RRLC-ESI-Q/TOF chromatograms (TCC) of (A) the solution of YZP, (B) 15 mixture references solution, (C) blank CSF samples, (D) drug CSF samples after oral admin-
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,  tetrahydropalmatine; 5, -allocryptopine; 7, coptisine; 8, tetrahydroberberine
anthotoxin; 18, bergapten; 19, oxypeucedanin; 20, imperatorin; and 21, isoimpera
00 L aliquot of ethyl acetate adding to 100 L of plasma sample
nd could be extracted completely within two times.
.3. Screening and analysis of prototype constituents and
etabolites in rat plasma and CSF
To clarify the active constituents responsible for pharmacologi-
al actions, it is necessary to ﬁrst acquire chemical proﬁles of TCM
erb medicine in vivo. Therefore, in this study, the RRLC-ESI-Q/TOF
echnique was developed to identify the multiple components in
lasma and CSF after oral administration of YZP extracts to Sprague-
awley rats. RRLC chromatograms of ﬁfteen mixture references
olution, the solution of YZP, blank samples (plasma and CSF), andoral administration of YZP extract from positive ion mode. Peaks: 1, protopine;
orydaline; 11, byakangelicin; 12, psoralen; 13, byakangelicol; 14, berberine; 17,
.
drug samples (plasma and CSF) after oral administration of YZP
extract were shown in Fig. 1. The retention time (tR), MS  data, and
fragments of absorbed constituents were listed in Table 1, and the
chemical structures of standards compounds were shown in Fig. 2.
The constituents in rat plasma and CSF after oral adminis-
tration of YZP extracts were well separated and identiﬁed by
their retention time and mass spectra. By comparing the chro-
matogram of YZP extract with that of the standards, twenty-one
peaks were identiﬁed in the plasma and seventeen peaks in the
CSF (Table 2). Among the twenty-one absorbable compounds
in plasma, ﬁfteen constituents (peaks 1, 3, 5, 7–9, 11–14, and
17–21) were identiﬁed as protopine, dl-tetrahydropalmatine,
-allocryptopine, coptisine, tetrahydroberberine, corydaline,
Y. Tao et al. / J. Chromatogr. B 935 (2013) 1– 9 5
Table 1
MS data of ESI-MS spectra and identiﬁcation of the YZP constituents.
Peak no. RT
(min)
Experimental
mass (m/z)
Calculated
mass (m/z)
Formula MS/MS (m/z) Source Identiﬁed compound
1 10.09 354.1331 354.1336 C20H19O5N 206.0804[RDA-
tetrahydroisoquinoline]
149.0596[RDA-benzene-ring]
Plasma, CSF Protopine
2  10.79 356.1863 192.1003,177.0789 Plasma Unknown
3  11.36 356.1887 356.1856 C21H25O4N 192.1005[RDA-
tetrahydroisoquinoline]
177.0789 [RDA-benzene-ring]
Plasma, CSF Tetrahydropalmatine
4  11.65 356.1861 192.1003,177.0784 Plasma, CSF Unknown
5  11.69 370.1678 370.1649 C21H23NO5 352.0931[M−H2O]+
206.0795[RDA-
tetrahydroisoquinoline]
165.0914[RDA-benzene-ring]
Plasma, CSF -Allocryptopine
6  12.24 324.1194 176.0694,149.0589 Plasma, CSF Unknown
7  12.48 320.0910 320.0917 C19H15NO4 292.0922[M−CO]+
262.0866[M−2CO-2H]+
Plasma Coptisine
8  13.59 340.1575 340.1543 C20H21O4N 176.0706[RDA-benzene-ring] Plasma, CSF Tetrahydroberberine
9  13.71 370.2010 370.2013 C22H27NO4 207.1205[RDA-
tetrahydroisoquinoline]
191.0897[RDA-benzene-ring]
Plasma, CSF Corydaline
10  15.32 305.1021 203.0331 Plasma, CSF Unknown
11  16.14 357.0901 335.1125 C17O18O7 231.0156[M−H2O-C5H8O]+
203.0348[M−H2O-C5H8O-CO]+
Plasma, CSF Byakangelicin
12  16.16 187.0384 187.0382 C11H6O3 159.1311[M−CO]+
144.0484[M−COCH3]+
131.0532 [M−2CO]+
Plasma Psoralen
13  16.18 317.1043 317.102 C17H16O6 287.0879[M−CH2O]+
203.0338[M−CH2O-C5H8O]+
175.0402[M−CH2O-C5H8O-CO]+
Plasma, CSF Byakangelicol
14  16.19 336.1192 336.1230 C20H18NO4 321.0995[M−CH3]+
292.0944[M−CH3-H-CO]+
Plasma, CSF Berberine
15  17.18 366.1706 366.1700 C22H24NO4 351.1445[M−CH3]+
336.1182[M−2CH3]+
322.1420[M−CH3-H-CO]+
308.1298[M−2CH3-CO]+
Plasma, CSF Dehydrocorydaline
16  17.89 352.1536 352.1543 C21H22NO4 337.1272[M−CH3]+
322.1078[M−2CH3]+
308.1268[M−CH3-H-CO]+
Plasma, CSF Palmatine
17  19.90 217.0508 217.0495 C12H8O4 202.0257[M−CH3]+
161.0598[M−2CO]+
Plasma, CSF Xanthotoxin
18  21.90 217.0504 217.0495 C12H8O4 202.0256[M−CH3]+
174.0322[M−CH3-CO]+
Plasma, CSF Bergapten
19  23.02 287.0877 287.0914 C16H14O5 203.0331[M−C5H8O]+ Plasma, CSF Oxypeucedanin
20  28.91 271.0958 271.0965 C16H14O4 203.0314[M−C5H8]+ Plasma, CSF Imperatorin
21  31.47 271.1097 271.0965 C16H14O4 203.0336[M−C5H8]+
159.0388[M−C H -CO ]+
147.
Plasma Isoimperatorin
T
b
b
c
o
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T
She ions at m/z 357.0901 were [M+Na]+.
yakangelicin, byakangelicol, berberine, psoralen, xanthotoxin,
ergapten, oxypeucedanin, imperatorin, and isoimperatorin by
omparing with the chromatographic-mass spectrometric analysis
f standard compounds. Peak 15 and 16 showed a quasi-molecular
on at m/z  366.1671 and m/z  352.1500 in MS  spectra respectively.
able 2
ummary of the metabolites of tetrahydropalmatine, protopine and corydaline in rat plas
No. RT (min) [M+H]+ Metabolic reaction 
M1-1 3.83 328.1539 2× demethylation 
M1-2 6.78 358.1646 Demethylation, hydroxylation
M1-3 8.01 372.1800 Hydroxylation 
M1-4 8.81 372.1800 Hydroxylation 
M1-5 9.21 342.1691 Demethylation 
M1-6 10.01 342.1695 Demethylation 
M2-1 4.79 342.1333 Demethylation, hydrogenation
M2-2 5.92 342.1365 Demethylation, hydrogenation
M3-1 4.90 400.1747 Hydroxylation, ketone format
M3-2 5.53 400.1753 Hydroxylation, ketone format
M3-3 7.63 400.1756 Hydroxylation, ketone format
M3-4 10.01 368.1854 Hydroxylation, dehydration 
M3-5 11.37 368.1853 Hydroxylation, dehydration 5 8 2
0438[M−C5H8-2CO]+
Meanwhile, m/z 351.1445 [M−CH3]+, m/z  322.1420[M−CH3-H-
CO]+ ions could be detected in MS/MS  spectra of peak 15. Similarly,
m/z 337.1272 [M−CH3]+, m/z 308.1248 [M−CH3-H-CO]+ ions could
be measured in MS/MS  spectra of peak 16. The same fragment
ions of both compounds at m/z 15 and m/z 42 were characteristic
ma.
Formula Source Parent compound
C19H21NO4 Plasma Tetrahydropalmatine
 C20H23NO5 Plasma Tetrahydropalmatine
C21H25NO5 Plasma, CSF Tetrahydropalmatine
C21H25NO5 Plasma, CSF Tetrahydropalmatine
C20H23NO4 Plasma, CSF Tetrahydropalmatine
C20H23NO4 Plasma, CSF Tetrahydropalmatine
 C19H19NO5 Plasma Protopine
 C19H19NO5 Plasma Protopine
ion C22H25NO6 Plasma Corydaline
ion C22H25NO6 Plasma Corydaline
ion C22H25NO6 Plasma Corydaline
C22H27NO5 Plasma Corydaline
C22H27NO5 Plasma Corydaline
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iig. 2. Chemical structures of standard compounds. 1, protopine; 3, tetrahydrop
yakangelicin; 12, psoralen; 13, byakangelicol; 14, berberine; 17, xanthotoxin; 18, 
ons to identify as dehydrocorydaline and palmatine according
o previous data [21,22]. However, these two components could
ot be conﬁrmed due to the lack of related standards. In addition,
our compounds (peaks 2, 4, 6, and 10) were unknown and require
urther study. Importantly, seventeen compounds (peaks 1, 3–6,
–11, and 13–20) were detected in CSF, suggesting that they had
assed through the blood-brain barrier (BBB), which might explain
he central analgesia effect of YZP.
The plasma metabolites were very helpful for revealing the
ioactive chemical basis of YZP. Up to now, the literature data
n the metabolism of YZP was still limited. Meanwhile, because
f complex chemical system, it was very difﬁcult to identify the
etabolites after the administration of the extracts of TCM formu-
ation. Thus, it was necessary to carry out the metabolism after the
dministration of single component and TCM formulation in order
o obtain the effective and reliable results. In the current studies,
hree constituents including protopine, tetrahydropalmatine and
orydaline which existed plentifully in YZP, were orally adminis-
rated individually in order to conclude the structures of the partial
etabolites of YZP. The detailed information of these metabolites,
ncluding the retention times, proposed elemental compositions,ine; 5, -allocryptopine; 7, coptisine; 8, tetrahydroberberine; 9, corydaline; 11,
ten; 19, oxypeucedanin; 20, imperatorin; 21, isoimperatorin.
and the molecule ions were listed in Fig. 3 and Table 2. After
oral administration of single compound, the results suggested that
tetrahydropalmatine was  metabolized into six metabolites by 2×
demethylation, demethylation and hydroxylation, hydroxylation
and demethylation, respectively. Protopine had occurred a reac-
tion of demethylation and hydrogenation into two metabolites.
Meanwhile ﬁve metabolites from corydaline were produced by
hydroxylation and ketone formation, hydroxylation and dehydra-
tion, respectively. At the same time, all those metabolites could be
detected in the rat plasma samples after oral administration of YZP
extracts.
3.4. Method validation
3.4.1. Linearity and LOQ
Regression equation, linear ranges, correlation of coefﬁcients
were shown in Table 3. All analytes’ calibrations exhibited excellent
linearity with coefﬁcients (r) higher than 0.992. As seen in Table 4,
LLOQ of protopine, -allocryptopine, tetrahydropalmatine, coryda-
line, tetrahyberberine and byakangelicin were 51.40, 48.02, 49.32,
44.91 34.01 and 9.29 ng/mL respectively, with accuracy (recovery)
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Table 3
Regression data regression of the analytes determined.
Analytes Linear equationa Correlation coefﬁcient (r) Linear range (ng/mL)
Protopine y = 14256x + 548,370 0.9921 50–5000
-Allocryptopine y  = 23596x + 748,610 0.9932 50–5000
Tetrahydropalmatine y = 18488x + 360,140 0.9992 50–5000
Tetrahyberberine y = 17212x + 499,280 0.9962 50–5000
Corydaline y = 26827x + 684,050 0.9986 50–5000
Byakangelicin y = 23596x + 748,610 0.9928 15–1500
a The regressive equations are presented as y = ax + b. y is the peak area, x is the concentration of compound.
Table 4
LLOQs of the analytes in the rat plasma (n = 6).
Analytes Measure conc. (ng/mL) Precision (% RSD) Accuracy (% recovery)
Protopine 51.40 ± 3.99 7.78 102.80
-Allocryptopine 48.02 ± 2.53 5.26 99.81
Tetrahydropalmatine 49.32 ± 2.81 5.71 96.10
Tetrahyberberine 44.91 ± 2.25 5.01 94.31
Corydaline 34.01 ± 3.64 7.76 95.25
Byakangelicin 9.29 ± 0.76 8.19 85.60
RSD: Relative standard deviation.
Table 5
The precisions, repeatability, matrix effects, recovery and stability of the analytes in the rat plasma (n = 6).
Analytes Spiked conc.
(ng/mL)
Precision Matrix effects
(%) (n = 6)
Recovery (%)
(n = 6)
Stability (RSD %, n = 6)
Intra-run
(RSD %)
Inter-run
(RSD %)
At room
temperature
for 6 h
At 10 ◦C in the
autosampler
for 24 h
Protopine 250 4.2 7.1 107.3 ± 2.9 93.8 ± 7.6 6.14 7.71
-Allocryptopine 250 7.0 5.8 107.8 ± 3.0 85.2 ± 8.8 4.79 6.70
Tetrahydropalmatine 250 3.9 6.3 105.2 ± 2.1 92.9 ± 8.2 7.12 4.54
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VTetrahyberberine 250 6.7 8.6 
Corydaline 250 3.5 7.2 
Byakangelicin 75 4.8 4.5 
etween 85.60% and 102.80% and precision (RSD) less than 8.13%,
hich was appropriate for quantiﬁcation of six analytes in the phar-
acokinetic study.
.4.2. Extraction recovery and matrix effect
A summary of matrix effect and extraction recovery was
hown in Table 5. The results of matrix effect for protopine, -
llocryptopine, tetrahydropalmatine, corydaline, tetrahyberberine
nd byakangelicin were 107.3 ± 2.9%, 107.8 ± 3.0%, 105.2 ± 2.1%,
07.2 ± 1.5%, 107.7 ± 3.3% and 98.9 ± 4.9% respectively, suggesting
hat no signiﬁcant suppression or enhancement of analytes’ ioniza-
ion took place by co-eluting endogenous substances in biological
atrix. Extraction recovery rates at the spike concentrations of
00 ng/mL from all analytes were between 98% and 108%, indicating
ufﬁcient extraction efﬁciency..4.3. Precision and stability
Assessment of precision and stability were listed in Table 5.
ntra- and inter-precision (relative standard deviation, RSD) of QC
able 6
harmacokinetic parameters of constituents after oral administration of YZP extracts.
No. RT (min) The analytes Cmax (g/L) 
1 10.09 Protopine 709.34 ± 146.38
2  11.36 Tetrahydropalmatine 858.26 ± 133.68
3  11.69 -Allocryptopine 232.18 ± 74.22 
4  13.59 Tetrahydroberberine 241.92 ± 58.63 
5  13.71 Corydaline 855.31 ± 172.94
6  16.14 Byakangelicin 206.54 ± 134.27
alues are expressed as mean ± standard deviation. F: bioavailability.07.2 ± 1.5 89.3 ± 7.9 8.23 6.72
07.7 ± 3.3 88.1 ± 8.9 5.35 8.63
98.9 ± 4.9 90.8 ± 6.7 5.76 8.13
samples was  less than 7.0% and 8.6%, respectively. The result of sta-
bility evaluation indicated that all analytes from rat plasma were
stable after culturing at an ambient temperature for 6 h and in the
autosampler at 10 ◦C for 24 h. Therefore, the resulting data showed
that the precision and repeatability of sample preparation were
satisfactory for pharmacokinetic study.
3.5. Pharmacokinetic studies
From the pharmacokinetic perspective, it was  considered that
compounds absorbed into the blood had a chance for showing
bioactivities. However, if there were some unreasonable phar-
macokinetic properties, such as a very short time in the body,
a constituent in the blood might not be a material basis for
efﬁcacy due to the lack of an effective blood concentration dur-
ing the treatment period. Therefore, pharmacokinetic proﬁles
of the absorbed components which were evaluated to ascer-
tain the effective compounds in vivo. The validated method of
RRLC-ESI-Q/TOF yielded results for the quantitation of protopine,
Tmax (h) AUC(0–t) (h h g/L) Cl/F (L/h/kg)
 4.60 ± 1.34 5570.82 ± 643.37 0.47 ± 0.05
 4.83 ± 2.14 5607.94 ± 471.05 0.86 ± 0.46
3.40 ± 0.55 1167.12 ± 266.13 3.11 ± 1.21
3.83 ± 1.94 1132.88 ± 277.16 1.01 ± 0.58
 3.67 ± 1.21 5861.09 ± 886.95 1.48 ± 0.85
 2.83 ± 0.75 655.41 ± 327.42 1.99 ± 1.16
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Fig. 3. The proﬁles of metabolites of (A) tetrahydropalmatine (M1-0), (B) protopine
(M2-0) and (C) corydaline (M3-0) in rat plasma after orally administered protopine,
tetrahydropalmatine and corydaline, at a dose of 1.0 mg/kg using Metabolite ID
software, individually.
Fig. 4. The mean plasma concentration versus time curve of protopine, -allocryptopin
administration of YZP in rats. Each point represents an average of six determinations andgr. B 935 (2013) 1– 9
-allocryptopine, tetrahydropalmatine, corydaline, tetrahyberber-
ine and byakangelicin in the rat plasma and has been applied to
the pharmacokinetic study after the oral administration of YZP
extracts in the rats. The mean plasma concentration versus time
curve was presented in Fig. 4. The results suggested that the plasma
concentrations of protopine, -allocryptopine, tetrahydropalma-
tine, corydaline, tetrahyberberine and byakangelicin in the rat
plasma were lower than LLOQ after 12, 8, 12, 12, 8 and 6 h, respec-
tively. Thus, more sensitive methods should be developed to study
the pharmacokinetics of YZP systemically in the future. However,
to our satisfaction, some main pharmacokinetic parameters were
obtained by non-compartment model based on statistical moment
such as Tmax, Cmax and AUC(0–t) et al. and showed in Table 6. The
results indicated that all analytes peaked between 3.5 and 5.0 h
and Cmax ranged from 214.6 to 858.3. The information described
above might be helpful for further pharmacokinetic studies on
YZP.
4. Conclusion
The RRLC-ESI-Q/TOF system was  proved to be a rapid and
efﬁcient for research the metabolic proﬁles of TCM formulation
systemically. In rat plasma, twenty-one prototype constituents
were detected in blood and ﬁfteen components were identi-
ﬁed by comparing with the chromatographic-mass spectrometric
analysis of standard compounds. Moreover, seventeen prototype
constituents were traced in rat CSF. Meanwhile, thirteen metabo-
lites in the blood were obtained and concluded by Metabolite ID
software after he administration of single component including
protopine, tetrahydropalmatine and corydaline and TCM formu-
lations, respectively. Importantly, a RRLC-ESI-Q/TOF method was
established and validated for the simultaneous quantiﬁcation
of protopine, -allocryptopine, tetrahydropalmatine, corydaline,
tetrahyberberine and byakangelicin in rat plasma and applied for
their pharmacokinetic research. These works could provide more
in-depth insights into the active components working in vivo and
would be helpful for further revealing the pharmacology and mech-
anism of YZP. However, since species difference usually existed
in the metabolism between the rat and human, further metabolic
research in human would be needed to carry out for better under-
standing of this formulation.
e, tetrahydropalmatine, corydaline, tetrahyberberine and byakangelicin after oral
 the error bars are standard deviations of the mean (n = 6).
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